

C4 THERAPEUTICS, INC.

Science and Technology Committee Charter

I. General Statement of Purpose

The Science and Technology Committee of the Board of Directors (the “**S&T Committee**”) of C4 Therapeutics, Inc. (the “**Company**”) on behalf of the Board of Directors (the “**Board**”) is responsible for assisting the Board’s oversight of the Company’s research and development (“**R&D**”) activities.

II. S&T Composition

The number of individuals serving on the S&T Committee shall be fixed by the Board from time to time but shall consist of no fewer than two members. The members of the S&T Committee shall be appointed by the Board and may be replaced or removed by the Board at any time with or without cause. Resignation or removal of the Director from the Board, for whatever reason, shall automatically constitute resignation or removal, as applicable, from this committee. Vacancies occurring, for whatever reason, may be filled by the Board. The Board shall designate one member of the S&T Committee to serve as Chair of the S&T Committee. The resignation of any member of the S&T Committee from the Board shall also constitute a resignation from the S&T Committee.

III. Meetings

The S&T Committee shall meet as often as it determines is appropriate to carry out its responsibilities. The S&T Committee may meet in person or by teleconference, video conference or other communications equipment by means of which all persons participating in the meeting can hear each other, with any additional meetings as deemed necessary or appropriate by the S&T Committee. If warranted, the Committee may keep minutes of meetings where formal decisions, if any, are taken. A majority of the members of the S&T Committee shall constitute a quorum for purposes of holding a meeting and the S&T Committee may act by a vote of a majority of members present at such meeting. In lieu of a meeting, the S&T Committee may act to take formal decisions by unanimous written consent.

IV. S&T Committee Responsibilities

The S&T Committee’s responsibilities shall be to:

A. Oversight of Company’s Scientific and Technology Endeavors

- Review, evaluate and advise the Board and the Senior Leadership Team regarding the long-term strategic goals and objectives and the quality and direction of the Company’s R&D programs.

- Review the overall scientific, clinical, regulatory and intellectual property strategy underlying the Company’s major R&D programs.
- Identify and discuss new and emerging trends in pharmaceutical science, technology and regulation and assure the Company makes well-informed choices in the investment of its R&D resources.
- Review the capability and skill set of the Company’s R&D organizations.
- Perform such other functions as requested by the Board from time to time.

B. Review of Charter

- Review and reassess the adequacy of this Charter annually and submit any proposed changes to the Board for approval.

C. Performance Evaluation of the S&T Committee

- Undertake periodically a performance evaluation of the S&T Committee and report to the Board on the results of such evaluation.

V. General

- The S&T Committee may establish and delegate authority to subcommittees consisting of one or more of its members when the S&T Committee deems it appropriate to do so to carry out its responsibilities.
- The S&T Committee shall make regular reports to the Board concerning areas of the S&T Committee’s responsibility.
- In carrying out its responsibilities, the S&T Committee shall be entitled to rely upon advice and information that it receives in its discussions and communications with management and such experts, advisors and professionals with whom the S&T Committee may consult. The S&T Committee shall have the authority to request that any officer or employee of the Company, the Company’s outside legal counsel, the Company’s independent auditor or any other professional retained by the Company to render advice to the Company attend a meeting of the S&T Committee or meet with any members of or advisors to the S&T Committee. The S&T Committee shall also have the authority to engage advisors to provide it with advice and information in connection with carrying out its responsibilities and shall have sole authority to approve any such advisor’s fees and other retention terms.

Adopted on December 16, 2022.